This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Tyson Foods, NetApp, NextEra Energy, The Ensign Group and Central Garden & Pet.
Why Central Garden (CENT) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Best Value Stocks to Buy for February 10th
by Zacks Equity Research
CENT and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 10, 2025.
Central Garden & Pet Q1 Earnings Top Estimates, Sales Rise 3% Y/Y
by Zacks Equity Research
CENT's strong performance in the first quarter was driven by the timing of shipments, strategic promotional activities and moderating inflation.
Central Garden (CENT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Central Garden (CENT) delivered earnings and revenue surprises of 800% and 4.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Central Garden & Pet Gears Up for Q1 Earnings: Key Factors to Note
by Zacks Equity Research
CENT's fiscal first-quarter earnings are likely to have shown softness in both Pet and Garden segments due to shifting market dynamics and reduced consumer spending.
Kellanova (K) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Kellanova (K) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Central Garden (CENT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Central Garden (CENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chewy Stock Trading at a Premium: Is the Best Buying Window Over?
by Sumit Singh
Chewy is well-positioned to capitalize on favorable dynamics and internal initiatives. However, rising costs and increased competition remain concerns.
Central Garden & Pet Dips 14% in a Month: Solid Bargain or Risky Bet?
by Zacks Equity Research
Technical breakdowns and declining demand spell trouble for CENT. Can it recover?
Central Garden (CENT) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Central Garden (CENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Central Garden & Pet Trades at a Premium: What's the Best Move Now?
by Zacks Equity Research
CENT stock's recent performance has driven its valuation, sparking questions about the future. Should you exercise caution, book profits or move on?
Central Garden & Pet Bumps Buyback Authorization: Key Factors to Note
by Swagata Bhattacharya
CENT raises its stock repurchase authorization to $130 million, citing the belief that it is currently undervalued.
Chewy Stock Up 37% YTD: What's the Best Move for Investors Now?
by Sumit Singh
Chewy is well-positioned to capitalize on favorable dynamics and internal initiatives. However, rising costs and increased competition remain concerns.
The Zacks Analyst Blog Highlights Chewy, Petco Health and Wellness, Central Garden & Pet and BARK
by Zacks Equity Research
Chewy, Petco Health and Wellness, Central Garden & Pet and BARK are included in this Analyst Blog.
Buy Chewy Stock Now? Key Tips to Note Ahead of Q3 Earnings
by Sumit Singh
Chewy's innovative strategies and growing footprint in the thriving pet care market make it a compelling investment case ahead of Q3 earnings.
CENT Posts Narrower-Than-Expected Q4 Loss, Sales Down 11% Y/Y
by Zacks Equity Research
Central Garden & Pet's fiscal fourth-quarter results reflect a net sales decline of 11%. Nonetheless, the company has been containing costs and simplifying its portfolio.
Central Garden (CENT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Central Garden (CENT) delivered earnings and revenue surprises of 10% and 7.51%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Central Garden & Pet Company to Post Q4 Earnings: Key Factors to Watch
by Zacks Equity Research
CENT's fourth-quarter earnings results are likely to indicate softness in the Pet segment owing to a decline in new pet adoptions.
Spectrum Brands (SPB) Q4 Earnings Miss Estimates
by Zacks Equity Research
Spectrum (SPB) delivered earnings and revenue surprises of -14.16% and 4.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Chewy Stock Still a Buy After a 96% Jump in Six Months?
by Sumit Singh
While Chewy's expansion initiatives drive growth, stiff competition and a premium valuation suggest investors should assess the stock's near-term potential.
Earnings Preview: Central Garden (CENT) Q4 Earnings Expected to Decline
by Zacks Equity Research
Central Garden (CENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Funko-A (FNKO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Funko-A (FNKO) delivered earnings and revenue surprises of 250% and 1.14%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Kellanova (K) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Kellanova (K) delivered earnings and revenue surprises of 7.06% and 2.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Chewy Stock a Buy, Sell or Hold at a P/E Multiple of 23.6X?
by Sumit Singh
Chewy's stock is currently trading at a discount following a recent decline. Is this a buying opportunity or a reason to hold off?